Guidance for Recognizing Central Nervous System Infections in Potential Deceased Organ Donors: What to Consider During Donor Evaluation and Organ Offers.

Slides:



Advertisements
Similar presentations
OPTN OPO Committee Spring 2012 Regional Meeting Update.
Advertisements

Participation Requirements for a Patient Representative.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation (Resolution 13) Ad Hoc.
UNOS Update.  Updating 2012 Strategic plan  Planning for OPTN and UNOS Strategic Planning RegionsBoard Executive Committee /CAC Community.
Ad Hoc Disease Transmission Advisory Committee Spring 2015.
Guidance to Organ Procurement Organizations for Allocation of Heart-Lung Blocks (Resolution 12) OPTN/UNOS Thoracic Organ Transplantation Committee Dr.
Recognizing Seasonal and Geographically Endemic Infections in Organ Donors: Considerations during Living Donor Evaluation (Resolution 16) Ad Hoc Disease.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
November 12, 2014 St. Louis, Missouri OPTN Strategic Planning Feedback Board of Directors.
Ad Hoc Disease Transmission Advisory Committee: A Report to the OPTN/UNOS Board Emily A. Blumberg, MD, Chair Michael D. Green, MD, MPH, Vice Chair Shandie.
Proposal to Require the Collection of Serum Lipase for all Pancreas Donors (Resolution 5) Pancreas Transplantation Committee Jonathan Fridell, MD, Chair.
Proposed Revisions to and Reorganization of Policy 6.0 (Transplantation of Non-Resident Aliens) Sponsors: Ad Hoc International Relations Committee and.
Proposed Revisions to Policy 6
Greater Consistency in Candidate and Deceased Donor HLA Typing Requirements Across Organ Types Histocompatibility Committee Spring 2014.
Addressing the Requirements Outlined in the HIV Organ Policy Equity Act Organ Procurement Organization Committee Spring 2015.
OPTN OPTN/UNOS Ethics Committee Spring 2012 Regional Meeting Update Chair, Alexandra Glazier, MPH, JD Vice-Chair, Peter Reese, MD.
Proposal to Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation Ad Hoc Disease.
Addressing the Requirements Outlined in the HIV Organ Policy Equity Act Organ Procurement Organization Committee Fall 2014.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
OPTN Proposal to Revise the Lung Allocation Score (LAS) System and Salient Activities of the Thoracic Organ Transplantation Committee.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
OPTN Proposal to Require Extra Vessels Disposition Reporting to the OPTN in Five Days of Transplant or Disposal Sponsored by the Operations and Safety.
Proposal to Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation Ad Hoc Disease.
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
Operations and Safety Committee Update Report to Board of Directors June , 2012 Phil Camp, Jr., MD - Chair.
11 Donor Derived Infections- Prevention, Recognition & Treatment Daniel Kaul MD Division of Infectious Disease University of Michigan.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Interim 1 algorithm for assessing pregnant women with a history of travel during pregnancy to areas with active Zika virus (ZIKV) transmission 2 Pregnant.
1 Improving Post-Transplant Communication of New Donor Information Ad Hoc Disease Transmission Advisory Committee Spring 2016.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
1 Infectious Disease Verification to Enhance Patient Safety Operations and Safety Committee.
Membership & Professional Standards Committee (MPSC)
White Paper: Ethical Considerations of Imminent Death Donation
Ad-hoc Disease Transmission Advisory Committee
Thoracic Organ Transplantation Committee
Clarify Informed Consent of Transmittable Conditions
Thoracic Organ Transplantation Committee
Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB
Ad Hoc Disease Transmission Advisory Committee (DTAC) Update
Clarify Informed Consent of Transmittable Conditions
Organ Procurement Organization Committee Report
Guidance on Requested Deceased Donor Information
OPTN/UNOS Thoracic Organ Transplantation Committee
Minority Affairs Committee Update
Thoracic Organ Transplantation Committee Spring 2019
Modify HOPE Act Variance to Include Other Organs
Ethical Implications of Multi-Organ Transplants (MOT)
VCA Data Collection and Submission
Thoracic Organ Transplantation Committee
Operations and Safety Committee
Vascularized Composite Allograft (VCA) Transplantation Committee
Guidance on Effective Practices in Broader Distribution
Vascularized Composite Allograft (VCA) Transplantation Committee
Thoracic Organ Transplantation Committee
Operations and Safety Committee
OPO Committee Fall 2014.
OPO Committee Fall 2014.
Minority Affairs Committee Update
Clarify Informed Consent of Transmittable Conditions
Vascularized Composite Allograft Transplantation Committee Fall 2014
Thoracic Organ Transplantation Committee
Vascularized Composite Allograft (VCA) Transplantation Committee
Vascularized Composite Allograft (VCA) Transplantation Committee
OPO Committee Fall 2014.
White Paper: Split Versus Whole Liver Transplantation
MPSC Transplant Program Performance Measures (Outcome Measures)
Vascularized Composite Allograft (VCA) Transplantation Committee
25 May 2019 Emerging issues: The new Council of Europe Guide for the Quality and Safety of Organs for Transplantation 7th International Congress Infection.
Presentation transcript:

Guidance for Recognizing Central Nervous System Infections in Potential Deceased Organ Donors: What to Consider During Donor Evaluation and Organ Offers Ad Hoc Disease Transmission Advisory Committee Dr. Emily Blumberg, Chair June 25, 2012

 CNS infection/Meningoencephalitis (ME) is not always recognized in donors  associated with high rates of transmission to organ recipients with subsequent morbidity and mortality  transmission can occur in the absence of clearly recognizable donor disease  some proven transmissions have involved donors with CNS syndromes that were not initially attributed to infection  of great concern due to the absence of effective treatments for most of these pathogens Background

 Reviewed aggregate data on potential donor-derived disease transmission reports for potential flags regarding meningoencephalitis (ME):  Donor age and cause of brain death?  Co-morbidities that may support stroke/CVA diagnosis ?  Fever at presentation of illness/admission?  Altered mental status and/or seizures part of the presentation?  CT /MRI of head or lumbar puncture consistent with infectious process?  Was the donor an immunosuppressed host?  Any potential environmental exposures associated with organisms causing ME? DTAC Findings

 2011 ATC abstract for oral presentation  Encephalitis Subcommittee discussed the data and developed a draft guidance document  Draft guidance document sent to organ specific and OPO committee leadership for feedback/discussion  Considerable feedback received from both OPO and Thoracic Organ Transplantation Committees  Modifications made as a result of this feedback to soften the language to be less prescriptive Document Development

 All donors with fever (without another obvious cause) at or soon after presentation of illness and/or otherwise unexplained altered mental status should be considered for further evaluation to rule out ME.  The potential donor should be discussed with the OPO’s Medical Director and, if possible, with Infectious Diseases and Neurology consultants.  Consideration should be given to performing a LP to look for evidence of ME, including non-bacterial pathogens.  Additional testing based on geographic and/or demographic factors may be considered as these results may guide post- transplant recipient management if the organs are utilized. Summary of Guidance

 If evidence suggests unsuspected or untreated CNS infection, caution should be considered in proceeding with allocation and acceptance of the organs for transplantation.  If ME is suspected and the suspected pathogen is one for which there are no treatment options (viral pathogens), extreme caution is urged before using any organs for transplant.  The risk must be balanced with risk of poor recipient outcome if this donor is not used.  Appropriate information should accompany the informed consent process. Where relevant, issues relating to these concerns should be discussed with the potential recipients. Summary of Guidance

 Guidance document will be posted on the OPTN website as a professional resource  Will be highlighted in UNOS Update and DTAC News e- newsletter If approved…

***RESOLVED, that the guidance document “Guidance for Recognizing Central Nervous System Infections in Potential Deceased Organ Donors: What to Consider During Donor Evaluation and Organ Offers” developed by the Ad Hoc Disease Transmission Advisory Committee is hereby approved, effective June 26, Unanimous DTAC Support for BOD Consideration

Thank you. Questions?